Published Aug 25, 2026 | 7:00 AM ⚊ Updated Aug 25, 2026 | 7:00 AM
Not every heart disease patient needs an LDL below 55 mg/dL.
Synopsis: The 2026 ACC/AHA dyslipidaemia guideline has lowered LDL-C targets and calls for earlier cardiovascular risk assessment. For India, experts said the framework is broadly relevant but should not be copied in its entirety. ICMR-INDIAB data showed widespread dyslipidaemia, often among younger adults without conventional risk factors, underscoring the need for India-specific, risk-based prevention.
The United States has lowered the bar for LDL cholesterol, the “bad” cholesterol that builds up in artery walls, for people at higher risk of heart disease. The move brings specific treatment targets back to the centre of cholesterol management and puts fresh emphasis on early risk detection.
The change came close on the heels of the 2026 ICMR-INDIAB study, which screened 121,078 adults across 36 states and Union Territories, and found that 87.3% of the sample population carried at least one lipid abnormality (an unhealthy reading in cholesterol, triglycerides, or related blood fats). Nearly nine in 10 Indian adults have something wrong with their lipid profile.
Together, the two developments raise an uncomfortable question for Indian clinicians. Can a framework built for American patients be applied to a population that develops heart disease roughly a decade earlier?
The 2026 dyslipidaemia (the medical term for abnormal levels of fats in the blood) guideline comes from the American College of Cardiology (ACC) and American Heart Association (AHA), alongside nine other medical organisations. It marks a real shift from the 2018 US approach.
The earlier guideline leaned on percentage reduction in LDL cholesterol (LDL-C, shorthand for LDL cholesterol level) from baseline. A reading of 70 mg/dL or higher in very-high-risk patients with established atherosclerotic cardiovascular disease, or ASCVD (heart or blood vessel disease caused by fatty build-up in the arteries), was mainly a threshold for considering extra non-statin treatment. Statins are the standard cholesterol-lowering drugs; non-statin options are used alongside or instead of them.
The new guideline restored specific LDL-C targets alongside percentage reduction. For high-risk primary prevention (treating people who have risk factors but have not yet had a heart attack or stroke), the goal is below 70 mg/dL. For people with established ASCVD who are at very high risk (meaning they have already had a cardiovascular event), it dropped to below 55 mg/dL, paired with a non-HDL-C goal under 85 mg/dL.
Non-HDL-C is total cholesterol minus the “good” HDL cholesterol, a broader marker of harmful particles in the blood. Patients with clinical ASCVD who are not at very high risk should aim for at least a 50% LDL-C reduction, with a goal below 70 mg/dL.
Not every heart disease patient needs an LDL below 55 mg/dL. The target depends on risk category, not diagnosis alone.
Risk assessment itself has also changed. The Pooled Cohort Equations, the older US formula for estimating heart disease risk, are no longer used. In their place came the PREVENT-ASCVD equations, a newer risk calculator used for adults aged 30 to 79 without established ASCVD or subclinical atherosclerosis (early artery build-up that hasn’t caused symptoms yet), estimating both 10-year and 30-year risk.
The guideline also recommended measuring lipoprotein(a), or Lp(a), a genetically inherited particle linked to heart risk that isn’t affected much by diet or exercise, at least once in adulthood. It expanded the role of ApoB, a protein that marks how many artery-clogging particles are in the blood, and gives coronary artery calcium scoring. This scan measures calcium deposits in the heart’s arteries.
The broader shift, in short, is from asking whether LDL is high to asking how much lifetime exposure a person has had to atherogenic (artery-damaging) lipoproteins, the particles that carry cholesterol through the blood.
The ICMR-INDIAB numbers gave the Indian side of the story.
Researchers drew lipid profiles from every fifth participant screened, arriving at a sample of 23,665 adults. They applied Lipid Association of India (LAI) criteria: total cholesterol at or above 200 mg/dL, triglycerides (another type of blood fat, linked to diet and metabolism) at or above 150 mg/dL, LDL-C at or above 100 mg/dL, and HDL-C, the “good” cholesterol that helps clear the bad kind, below 40 mg/dL in men or 50 mg/dL in women.
Low HDL cholesterol was the biggest driver, present in 66.8% of the samples. High LDL followed at 49.4%, then high triglycerides at 29.5%, followed by high total cholesterol at 22.1%.
Urban residents showed higher rates than rural residents (89.0% versus 86.5%), and women showed higher rates than men (91.1% versus 83.5%).
Prevalence rose with body mass index (BMI, a height-to-weight ratio used to estimate healthy weight), worsening glucose tolerance and hypertension. It also peaked early. Dyslipidaemia hit adults aged 30 to 39 the hardest, a pattern the study’s authors link to the Asian Indian phenotype of abdominal fat and insulin resistance at BMI levels considered normal elsewhere.
That age pattern is not a footnote. It is at the heart of the debate over whether India should adopt the American approach.
Also Read: Vitamin D deficiency linked to six-fold increase in heart disease risk
Dr V Mohan, chairman of Dr Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation, is a co-author of the ICMR-INDIAB study. He does not see the American guideline in conflict with the Indian recommendations.
“The new 2026 ACC/AHA guideline is an important development in the management of dyslipidaemia,” he told South First. Its greater emphasis on overall cardiovascular risk, lifetime risk and appropriate LDL cholesterol targets is relevant to India too.
India already runs its own risk-based framework through the Lipid Association of India, built around lifetime cardiovascular risk, early prevention and factors beyond LDL cholesterol.
“I would not see the new ACC/AHA guideline and the Indian recommendations as being in conflict,” Dr Mohan said. “Rather, they provide an opportunity to further strengthen cardiovascular prevention in India.”
Dr Vithal D Bagi, senior cardiologist at Apollo Hospitals Bannerghatta Road, Bengaluru, agreed on the substance but pushed harder for a separate Indian approach.
“Indians develop coronary artery diseases one decade earlier than the Western population,” he says to South First. Indian guidelines, he adds, already place more emphasis on non-HDL-C and ApoB than on LDL-C alone, a marker set the American guideline treats as secondary.
Also Read: Most heart attacks can be reversed in the initial golden hours
Here is the twist. The new American thresholds of 70 mg/dL and 55 mg/dL are not, in most cases, more aggressive than what Indian specialists already use.
Dr Bagi spread out the LAI risk bands directly: below 100 mg/dL for low-to-moderate risk, below 70 mg/dL for high risk, below 50 mg/dL for very high risk, and below 30 mg/dL for extreme risk.
“Indians have a higher predisposition to aggressive atherosclerosis,” the hardening and narrowing of arteries from fatty build-up, he said, pointing to higher triglycerides, Lp(a) and ApoB, low HDL-C, and more harmful LDL particle types.
Dr Mohan termed the American targets reasonable, but resisted turning them into a blanket rule.
“I would not interpret this as meaning that every Indian should have an LDL cholesterol below 70 mg/dL,” he said. The tightest goals, below 50 mg/dL and lower, are for patients with diabetes carrying added risk or established ASCVD, following LAI recommendations.
“The appropriate LDL-C target should be individualised according to the person’s overall cardiovascular risk,” he said, drawing a line between someone who has already had a heart attack and a young person with only mildly elevated cholesterol.
Also Read: Did you know that most serious heart attacks happen on Mondays?
PREVENT-ASCVD replaces a US risk calculator that has been in use for more than a decade. The question for India is whether a tool built from American population data could capture a disease pattern that shows up years earlier here.
“ASCVD risk calculator is conventionally used for those above forty years of age in the Western population; that is not applicable in Indians,” Dr Bagi said. He wanted better risk scores built for younger Indian adults, alongside earlier lifestyle intervention and lifetime risk assessment.
Dr Mohan took a more measured line. He was unwilling to write off conventional calculators, but argued that no calculator could capture every factor behind lifetime cardiovascular risk.
The Indian framework, he said, increasingly folds in lifetime risk, family history, subclinical atherosclerosis, non-HDL cholesterol. ApoB. Lp(a) testing is useful too, particularly for people with premature cardiovascular disease or a strong family history.
Also Read: What is winter heart attack?
One finding from the ICMR-INDIAB study further complicated matters. About 40% of people with dyslipidaemia had none of the usual red flags: no diabetes, no hypertension, no obesity. The study estimated that it could represent roughly 354.7 million Indians.
“Dyslipidaemia was also present in about 40% of individuals who did not have diabetes, hypertension or obesity,” Dr Mohan said.
This does not prove that dyslipidaemia develops before those conditions. It shows something narrower but still important: plenty of people can have abnormal lipids while showing none of the conventional metabolic warning signs.
For Dr Mohan, that is a reason to broaden screening, not to throw out risk calculators altogether.
“I would not say that conventional risk calculators are necessarily inadequate,” he said. But doctors should not assume someone has no lipid-related risk simply because diabetes, hypertension and obesity are absent.
“A person may appear healthy on the outside and still have an abnormal lipid profile,” he said. “Detecting these abnormalities early allows us to prevent cardiovascular disease before it develops.”
Dr Bagi extended the same point to treatment. Atherosclerosis, he noted, runs on multiple contributing factors beyond LDL-C, including diabetes, hypertension, smoking, obesity, stress, poor sleep and inactivity. For Indians with dyslipidaemia and no other obvious risk factor, LDL-C and non-HDL-C targets deserve the same discipline usually reserved for blood pressure or HbA1c, a blood test that tracks average blood sugar over a few months, targets in hypertensive or diabetic patients.
“The lower the modifiable risk factors,” he said, “the lower the cardiovascular risk.”
A narrower, more technical dispute is also buried in the data.
The ICMR-INDIAB study calculated LDL-C using the Friedewald equation, the standard formula that estimates LDL-C from total cholesterol, HDL-C and triglycerides rather than measuring it directly with a lab test.
Dr Bagi felt that it undercounts the real number in Indian patients. “Conventional formula-based LDL-C assessment underestimates the LDL-C value based on the Friedewald formula,” he said. “Direct LDL-C should be assessed.”
Dr Mohan was more cautious about what the study could actually prove. “I would not say that our study by itself proves that the LDL-C threshold should be lowered for every Indian,” he says. The study was designed to map prevalence, not to pin down the exact LDL-C level at which cardiovascular events occur.
What it does show clearly, he said, is that looking at LDL cholesterol alone does not give the complete picture. Non-HDL cholesterol, ApoB and Lp(a) all deserve a place alongside it.
The age curve in the ICMR-INDIAB data carried weight beyond the topline number. Dyslipidaemia prevalence peaked among adults aged 30 to 39, then held through middle age in women and declined only modestly in men after 50.
Dr Mohan saw this as a case for earlier screening, not earlier medication. “Waiting until a person develops diabetes, hypertension or established cardiovascular disease before assessing their lipid profile may represent a missed opportunity for prevention,” he said.
His message to younger adults is direct: don’t wait until a heart problem appears before thinking about cardiovascular health.
Dr Bagi treated the same finding as an argument against borrowing age cutoffs wholesale from the West. India, he said, needs risk scores built for a younger population, not adapted from one that reaches the same risk a decade later.
Set side by side, the ICMR-INDIAB numbers and the 2026 American guideline pointed to more than a simple choice between adopting the framework or rejecting it.
Both experts viewed the American targets as a useful reference point that Indian practice already runs ahead of in places, particularly LDL-C thresholds for high-risk patients, while lagging in others, particularly the age at which screening should start.
Dr Mohan summed up the direction he would prefer: risk-based treatment and appropriate LDL lowering, rather than one target applied to everyone.
Dr Bagi’s closing argument rested on numbers rather than principle. Lower LDL-C and non-HDL-C, tracked as closely as blood sugar or blood pressure, translate directly into lower cardiovascular risk, for a population that reaches that risk roughly a decade sooner than the guideline’s country of origin.
The ICMR-INDIAB study has provided policymakers with an uncomfortable picture. Lipid abnormalities often show up before diabetes, hypertension or obesity do, sometimes well before age 40. Mohan puts it plainly: cardiovascular prevention needs to look beyond diabetes, blood pressure and body weight, and include proper assessment of lipid abnormalities and other risk factors.
The new American guideline, then, is not a template India should copy altogether. Its more useful contribution may be the shift it represents: towards catching cardiovascular risk earlier, weighing lifetime exposure, and treating people according to their actual risk rather than a single number on a lab report.
For India, where risk can build quietly while a person still looks and feels metabolically healthy, the harder task is not deciding which target to chase. It is finding that risk early enough to act on it, before the first heart attack reveal the risk.
(Edited by Majnu Babu).
